MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Начало・Списък с акции・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Затворен

1.31 -6.43

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.28

Максимум

1.39

Ключови измерители
By Trading Economics
Приходи	8M -50M
EPS	-0.82
Служители	171
EBITDA	7.9M -48M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+283.21% upside

Дивиденти
By Dow Jones
Следващи печалби	2.05.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	6M 90M
Предишно отваряне	7.74
Предишно затваряне	1.31

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

1.242 / 1.47 Подкрепа & съпротива

Pliant Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.04.2025 г., 23:55 ч. UTC

Горещи акции

Stocks to Watch: RH, Nike, Dollar Tree, Apple

2.04.2025 г., 22:50 ч. UTC

Значими двигатели на пазара

E.l.f. Beauty, Estee Lauder, Coty Shares Fall on Reciprocal Tariffs Hit

2.04.2025 г., 21:08 ч. UTC

Печалби

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs -- Update

2.04.2025 г., 21:00 ч. UTC

Печалби

RH 4Q Revenue Misses Guidance, Looks to Offset Reciprocal Tariffs

2.04.2025 г., 23:56 ч. UTC

Пазарно говорене

Gold Rises as Trump's Tariffs Enhance Safe-Haven Appeal -- Market Talk

2.04.2025 г., 23:44 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

2.04.2025 г., 23:44 ч. UTC

Пазарно говорене

Nikkei Likely to Fall After U.S. Tariff Plan -- Market Talk

2.04.2025 г., 23:44 ч. UTC

Топ новини

Some GOP Senators Break With Trump to Reject Canada Tariffs -- WSJ

2.04.2025 г., 23:32 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

2.04.2025 г., 23:32 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

2.04.2025 г., 23:32 ч. UTC

Пазарно говорене

Trump's Tariffs on Australia Conspicuously Unfriendly -- Market Talk

2.04.2025 г., 23:12 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

2.04.2025 г., 23:12 ч. UTC

Пазарно говорене

Trump Tariff 'Blow Bigger Than We Expected,' Capital Economics Says -- Market Talk

2.04.2025 г., 23:10 ч. UTC

Пазарно говорене

Canada, Mexico Get Short-Term Advantage From Trump's Tariff Moves -- Market Talk

2.04.2025 г., 23:09 ч. UTC

Пазарно говорене

U.S. Effective Tariff Rate Highest in 131 Years -- Market Talk

2.04.2025 г., 23:09 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

2.04.2025 г., 22:57 ч. UTC

Пазарно говорене

Australia Spared Worst Of US Tariff Hikes -- Market Talk

2.04.2025 г., 22:56 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

2.04.2025 г., 22:56 ч. UTC

Пазарно говорене

US Equity Futures Down as Tariff Hikes Stoke Recession Fears -- Market Talk

2.04.2025 г., 22:43 ч. UTC

Топ новини

Придобивния, сливания и поглъщания

AppLovin, Amazon Emerge as TikTok Bidders Ahead of Trump's Deadline, Sources Say -- 2nd Update

2.04.2025 г., 22:12 ч. UTC

Пазарно говорене

Trump's Tariff Order May Set Path for New U.S.-Canada Pact -- Market Talk

2.04.2025 г., 21:48 ч. UTC

Топ новини

The Stock Market Pain Is Just Getting Started. 'This is How You Sabotage the World's Economic Engine.' -- Barrons.com

2.04.2025 г., 21:41 ч. UTC

Пазарно говорене

USD Reaction To Trump's Tariffs Limited So far -- Market Talk

2.04.2025 г., 21:17 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

2.04.2025 г., 21:17 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

2.04.2025 г., 21:17 ч. UTC

Пазарно говорене

Mexican Peso Gains as Worst Tariff Fears Avoided -- Market Talk

2.04.2025 г., 21:04 ч. UTC

Топ новини

Trump's Tariffs Could Blow Up Big Pharma's Tax Shelter -- Heard on the Street -- Update

2.04.2025 г., 21:03 ч. UTC

Пазарно говорене

Treasury Yields, Dollar, Stock Futures Fall as Markets Digest Tariffs -- Market Talk

2.04.2025 г., 20:53 ч. UTC

Печалби

Kaiser Aluminum Changes Method From Last-In, First-Out to Weighted Avg Cost Effective Jan. 1, 2025

2.04.2025 г., 20:52 ч. UTC

Печалби

Kaiser Aluminum Changes Inventory Acctg Methodology

Сравнение с други в отрасъла

Ценова промяна

Pliant Therapeutics Inc Прогноза

Ценова цел

By TipRanks

283.21% нагоре

12-месечна прогноза

Среден 5.25 USD 283.21%

Висок 17 USD

Нисък 1.5 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Pliant Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

13 ratings

Купи

Задържане

Продай

Според 13 анализатори, дали борсови рейтинги на Pliant Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.242 / 1.47Подкрепа & съпротива

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.